Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01243151 · ClinicalTrials.gov registry record · Phase 1
Safety And Tolerability Of Multiple Doses Of PF-04950615 (RN316) In Subjects With Hypercholesterolemia
A Phase 1 study of Hypercholesterolemia and Dyslipidemia, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 68
- Enrollment target
- 9
- Study locations
NCT01243151: Completed Phase 1 study of Hypercholesterolemia and Dyslipidemia, sponsored by Pfizer.
NCT01243151 is a Phase 1 study of Hypercholesterolemia and Dyslipidemia that has completed, run by Pfizer. The registered enrollment target is 68 participants, below the 816-participant average among 62 other Hypercholesterolemia trials with a reported enrollment target (92% lower). The trial reports 9 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01243151, a Phase 1 study of Hypercholesterolemia and Dyslipidemia, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 68 participants
- Enrollment target
- 9
- Study locations
Study Summary
The primary objective of this study is to evaluate the safety and tolerability of repeated doses of PF-04950615 (RN316) in study volunteers with hypercholesterolemia. PF-04950615 is an investigational drug that is currently being studied as a lipid lowering agent.
Primary Outcome
An AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. Dose limiting and intolerable treatment-related AEs were the AEs resulting from drug overdose, drug withdrawal, drug abuse, drug misuse, drug interactions, drug dependency, extravasation, exposure in utero, exposure during breast feeding.
Conditions Studied
Interventions
- BIOLOGICAL PF-04950615 (RN316)
Study Locations (9)
California
- California Clinical Trials Medical Group - Culver City
- Glendale Adventist Medical Center - Glendale
Florida
- SeaView Research, Inc. - Miami
- SeaView Research, Inc. - Miami
Kansas
- Vince and Associates Clinical Research - Overland Park
- Vince and Associates Clinical Research - Overland Park
Hawaii
- Covance Clinical Research Unit, Inc. - Honolulu
Minnesota
- Prism Research - Saint Paul
Texas
- Healthcare Discoveries, LLC dba ICON Development Solutions - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 68 participants |
| Start Date | 2011-02 |
| Est. Completion | 2011-10 |
| Phase | Phase 1 |
What the finished NCT01243151 record still lists
NCT01243151 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 68 participants, a relatively small participant target, below the 816-participant average among 62 other Hypercholesterolemia trials with a reported enrollment target (92% lower).
The record links to 2 conditions, with Hypercholesterolemia appearing as the primary indexed condition, and to 1 intervention - of which PF-04950615 (RN316) is the first listed.
NCT01243151 lists 9 locations in 6 states (California, Florida, Kansas).
Frequently Asked Questions
What is clinical trial NCT01243151 about?
NCT01243151 is a clinical study titled "Safety And Tolerability Of Multiple Doses Of PF-04950615 (RN316) In Subjects With Hypercholesterolemia". The primary objective of this study is to evaluate the safety and tolerability of repeated doses of PF-04950615 (RN316) in study volunteers with hypercholesterolemia. PF-04950615 is an investigational drug that is currently being studied as a lipid lowering agent.
What is the current status of trial NCT01243151?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 68 participants. The study started on 2011-02. Estimated completion is 2011-10.
What conditions does trial NCT01243151 study?
This clinical trial studies the following conditions: Hypercholesterolemia, Dyslipidemia.
What interventions are being tested in trial NCT01243151?
The interventions under investigation include: PF-04950615 (RN316) (BIOLOGICAL).
Who is sponsoring clinical trial NCT01243151?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01243151 being conducted?
This trial has 9 study locations across California, Florida, Hawaii, Kansas, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypercholesterolemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01243151's enrollment target sits among peer trials
68 48th of 62 higher than 15 of 62 other Hypercholesterolemia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hypercholesterolemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of the Response of Human Small Blood Vessels
COMPLETED · Phase 1
-
A Study of LY3015014 in Healthy Participants With High Cholesterol
COMPLETED · Phase 1
-
Safety, Tolerability, PK and PD of LGT209 in Healthy Volunteers and Patients With Hypercholesterolemia
COMPLETED · Phase 1
-
Pilot Program to Improve Statin Adherence and Lower Cholesterol in Older Adults
COMPLETED · Phase 1
-
Potential Risk Factors for Stroke
COMPLETED · Phase 1
-
Ascending Multi-dose Study of REGN727(SAR236553) With and Without Concomitant Atorvastatin
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02044497 · 68 participants · Phase 4
Population Pharmacokinetics and Pharmacogenomics of Oral Oxycodone in Pediatric Surgical Patients
- NCT03779854 · 68 participants · Phase 2
Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant
- NCT03821246 · 68 participants · Phase 2
Neoadjuvant Atezolizumab-Based Combination Therapy in Men With Localized Prostate Cancer Prior to Radical Prostatectomy
- NCT04115514 · 68 participants · Phase 2
Treatment of ARDS With Instilled T3
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia